22211 WEST INTERSTATE-10, SAN ANTONIO, TX
Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Advances CyPath® Lung for Surveillance of Lung Cancer Survivors
Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Other Events, Press Release
Technologies and Pictor®, Inc. Partner to Develop and Commercialize Diagnostics for Asthma and COPD
Q2
FY 2025
Q3
Q1
Amended Annual Report
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(4)
Amended Registration Statement for Securities
S-1
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
PRER14A
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement